image
Healthcare - Medical - Devices - NYSE - US
$ 13.055
0.115 %
$ 1.1 B
Market Cap
-19.78
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one FNA stock under the worst case scenario is HIDDEN Compared to the current market price of 13.1 USD, Paragon 28, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one FNA stock under the base case scenario is HIDDEN Compared to the current market price of 13.1 USD, Paragon 28, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 31, 2025.

The intrinsic value of one FNA stock under the best case scenario is HIDDEN Compared to the current market price of 13.1 USD, Paragon 28, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart FNA

image
$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 Mar
FINANCIALS
256 M REVENUE
18.39%
-40.8 M OPERATING INCOME
10.70%
-54.6 M NET INCOME
5.03%
-27.1 M OPERATING CASH FLOW
57.51%
-15.7 M INVESTING CASH FLOW
41.88%
293 K FINANCING CASH FLOW
-99.77%
71.7 M REVENUE
15.10%
-6.43 M OPERATING INCOME
23.87%
-11.1 M NET INCOME
23.33%
-3.28 M OPERATING CASH FLOW
-23.88%
-2.61 M INVESTING CASH FLOW
32.09%
-377 K FINANCING CASH FLOW
-283.46%
Balance Sheet Paragon 28, Inc.
image
Current Assets 169 M
Cash & Short-Term Investments 34.6 M
Receivables 39 M
Other Current Assets 95.3 M
Non-Current Assets 122 M
Long-Term Investments 0
PP&E 71.4 M
Other Non-Current Assets 50.5 M
11.89 %13.42 %32.76 %24.55 %17.37 %Total Assets$290.7m
Current Liabilities 48.1 M
Accounts Payable 16 M
Short-Term Debt 640 K
Other Current Liabilities 31.5 M
Non-Current Liabilities 112 M
Long-Term Debt 0
Other Non-Current Liabilities 112 M
9.98 %19.68 %69.94 %Total Liabilities$160.1m
EFFICIENCY
Earnings Waterfall Paragon 28, Inc.
image
Revenue 256 M
Cost Of Revenue 64.7 M
Gross Profit 191 M
Operating Expenses 232 M
Operating Income -40.8 M
Other Expenses 13.9 M
Net Income -54.6 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)256m(65m)191m(232m)(41m)(14m)(55m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.75% GROSS MARGIN
74.75%
-15.92% OPERATING MARGIN
-15.92%
-21.33% NET MARGIN
-21.33%
-41.84% ROE
-41.84%
-18.79% ROA
-18.79%
-17.13% ROIC
-17.13%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Paragon 28, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)202020202021202120222022202320232024202420252025
Net Income -54.6 M
Depreciation & Amortization 18.5 M
Capital Expenditures -16.9 M
Stock-Based Compensation 13 M
Change in Working Capital -15.5 M
Others 1.6 M
Free Cash Flow -44.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Paragon 28, Inc.
image
Wall Street analysts predict an average 1-year price target for FNA of $13 , with forecasts ranging from a low of $11 to a high of $15 .
FNA Lowest Price Target Wall Street Target
11 USD -15.74%
FNA Average Price Target Wall Street Target
13 USD -0.42%
FNA Highest Price Target Wall Street Target
15 USD 14.90%
Price
Max Price Target
Min Price Target
Average Price Target
1616141412121010886644May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Paragon 28, Inc.
image
Sold
0-3 MONTHS
33.3 M USD 1
3-6 MONTHS
5.18 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Investors to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 2 weeks ago
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Investors to Connect NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Stockholders to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 3 weeks ago
Shareholder Alert: The Ademi Firm Investigates Whether Paragon 28, Inc. is Obtaining a Fair Price for its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Paragon 28 (NYSE: FNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Zimmer Biomet. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Paragon 28 shareholders will receive only $13.00 per share in cash, corresponding to an equity value. businesswire.com - 3 weeks ago
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer Biomet”). The expiration of the waiting period under the. businesswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Investors to Inquire about Securities Investigation NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Investors to Reach Out NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 3 weeks ago
Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons (“AAOS”). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case man. businesswire.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Stockholders to Reach Out NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accessnewswire.com - 1 month ago
FNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paragon 28, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash is fair to Paragon 28 shareholders. Paragon 28 shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved. Halper Sadeh encourages Paragon 28 shareholders to click here to learn more. businesswire.com - 1 month ago
8. Profile Summary

Paragon 28, Inc. FNA

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.1 B
Dividend Yield 0.00%
Description Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Contact 14445 Grasslands Drive, Englewood, CO, 80112 https://www.paragon28.com
IPO Date Oct. 15, 2021
Employees 525
Officers Dr. Matthew Millard Chief Human Resources Officer Mr. Albert DaCosta Co-Founder, Chairman, President & Chief Executive Officer Mr. Robert S. McCormack J.D. General Counsel & Secretary Mr. Matthew Jarboe Executive Vice President of Sales & Chief Commercial Officer Mr. Andrew James Hill Executive Vice President of Research & Development Mr. Chadi Chahine Chief Financial Officer & Executive Vice President of Supply Chain Operations Mr. Matthew Brinckman Senior Vice President of Strategy & Investor Relations Mr. John Shumaker Executive Vice President of Sales - U.S. Mr. Hans Kestler Executive Vice President of International Mr. Brendan Shook Executive Vice President of Marketing & Medical Education